Pics 6: Lymphoid/PCD Flashcards by Victoria DeVito

Q

HL subtypes and frequency of each

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Difference between cHL and NLPHL
New name for NLPHL

A

NLPBCL

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Early stage HL: prognostic markers
GHSG vs EORTC

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Prognostic in Advanced stage cHL

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

PET Deauville scores

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Early stage cHL, favourable
4 options, which trials

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Early stage HL, unfavourable
4 options, trials

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Advanced stage cHL
2 main options in 2024
What were the prior 3 options

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HL conclusions 1

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HL early stage conclusions

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HL advanced stage conclusions, R/R

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

New therapies in HL, conclusions

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

WM/LPL DDX

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Special toxicities of drugs used in WM
Ritux
Flu/Clad
Benda
Bortez
Ibrutinib

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

1L treatment of WM
2nd line
MAG neuropathy
Bing Neel
Intolerant or refractory to Ibrutinib

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid staging tests

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid algorithm for workup

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid AutoSCT transplant eligibility

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid treatment approach

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

POEMS diagnostic criteria

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Natural history of MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

MGUS risk stratification, risk groups, recommended monitoring

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

IMWG criteria for MGUS/SMM/MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

MGRS types
Glomerular vs Tuuloisterstitial vs vascular
Which 2 types deposit everywhere?

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

SMM what is the 20-20-20 rule? Risks of progression

R-ISS for MM

MM treatment paradigm, phases of therapy for Fit vs Unfit/not Auto

Approved therapies in MM over the years

IMWG response criteria for MM

R/R MM definition

Backbones of therapy for MM early relapse

Plasmacytoma evaluation and therapy algorithm

Solitary plasmacytoma diagnostic criteria Solitary bone Solitary extra medullary Solitary with minimal marrow involvement MM

Plasma cell dyscrasia summary slide

Deauville scale for PET uptake

Risk factors for early stage HL EORTC or GHSG

CVD incidence in HL survivors for RT or anthracycline

Frontline chemo regimens in HL What drugs are in: A-AVD ABVD escBEACOPP

Longterm followup for HL survivors

MM pathology images

DDX of monoclonal gammopathies table

MGUS: factors that influence risk of progression

Uncommon and rare plasma cell disorders

SMM risk factors for progression

Symptoms in MM and pathophys

Prognostic factors in MM 8 tumor related 5 host related

IMWG 2016 relapse definition

R-ISS staging for MM

IMWG response criteria for MM, complicated table

Drug classes and examples in MM

R/R MM regimens and trials

Dose levels, modifications for frailty, meds in MM Bortez, Len, Dex, Melph, Fred, Cyclophos

Organ involvement in Amyloid, characteristics of each

Hematologic response criteria in amyloid

Organ response criteria in amyloid

Cell of origin for B cell NHLs

Lugano criteria staging for NHL

GELF criteria for high tumor burden, when to treat

FLIPI scoring parameters

FL progression/transformation slide RFs for transformation

MALT lymphoma, antigen triggers and which MALT lymphoma? What translocation to predict resistance of lymphoma to H pylori eradication

FL relapses, treatment strategies at each time

Mantle cell treatment overview Fit/young vs old/unfit

Summary slide: indolent lymphomas and mantle cell

IHC/Flow markers and lineages

B cell development, and which malignancies from which cell of origin

RFs for NHL

T cell development and associated neoplasms

Phenotypic markers for different lymphomas

DLBCL IPI in rituximab era Which RFs?

APLES Age>60 PS 2+ LDH >1 extra nodal site Stage 3/4

Lugano staging system table

FLIPI Score

NO-LASH

MIPI score

Age PS LDH WBC count

Approach to ND FL patient, by tumor burden and symptoms

GELF criteria for high tumor burden

iwCLL indications to treat CLL

CLL-IPI

Frontline BTKi vs Ven+O pros/cons

CLL conclusion slide

Chronic B cell LPDs, immunophenotypes

CLL staging: Stage, Binet, Rai

BCR signalling in CLL, drugs used and their targets

CLL-IPI table

Treatment algorithm for previously untreated CLL

Indications for starting therapy in CLL, and precautions table

PTCL types by presentation Leukemic Nodal Other extra nodal

Survival by different TCLs Common vs Uncommon Best vs worst

PTCL initial management

ATLL approach by subtype 4 subtypes

Mgmt cutaneous TCL early vs advanced stages

IPI for DLBCL

Rituximab MOA What types of cell killing? Risks of Ritux

DLBCL frontline treatment summary

RCHOP in DLBCL Drugs and dosages How long is a cycle? Common toxicities

Polatuzumab MOA What indications?

DLBCL untreated DLBCL r/r

CAR-T vs ASCT in DLBCL Trials, and which drugs

R/R DLBCL Guide to picking next therapy R/R >/< 12 mo prior ASCT prior CART ineligible for ASCT/CART

3 types of Burkitt Lymphoma, and characteristics Who, where, EBV status?

Burkitt teaching points slide

Aggressive B cell lymphoma survivorship/followup